Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 14/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 14/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylamine SCHEMBL10474969 | 0.80 | PDE3B (0.95) | PDE3BPDE3ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3723997 | 0.80 | PDE3B (1.00) | PDE3BPDE3ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3723998 | 0.80 | PDE3B (1.00) | PDE3BPDE3ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5677129 | 0.79 | PDE3B (0.46) | PDE3BPDE3ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5677114 | 0.79 | PDE3B (0.46) | PDE3BPDE3ASMN1; SMN2KDM4EALDH1A1 | |
| Dimethylamine SCHEMBL10475180 | 0.78 | PDE3B (0.95) | PDE3BPDE3ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5675187 | 0.77 | PDE3B (0.66) | PDE3BPDE3ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5675188 | 0.77 | PDE3B (0.66) | PDE3BPDE3ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5681194 | 0.77 | SMN1; SMN2 (0.51) | PDE3BPDE3ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5681207 | 0.77 | SMN1; SMN2 (0.51) | PDE3BPDE3ASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265871-B1 | PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE | ORION CORP (FI) | 2006-02-08 | — | — | EP | disclosed |
| US-6699868-B2 | INCREASE THE CALCIUM SENSITIVITY OF CONTRACTILE PROTEINS OF THE CARDIAC MUSCLE | ORION CORPORATION (FI) | 2004-03-02 | — | — | US | disclosed |
| US-20030158200-A1 | Pyridazinyl phenyl hydrazones useful against congestive heart failure | ORION CORPORATION (FI) | 2003-08-21 | — | — | US | disclosed |
| EP-1265871-A1 | PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE | ORION CORPORATION (FI) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001068611-A1 | PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE | ORION CORPORATION (FI) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158200-A1 | Pyridazinyl phenyl hydrazones useful against congestive heart failure | FABP3, TNNI3, TNNT2 | PDE3B 1154/4885PDE3A 667/4885SMN1; SMN2 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.